News | May 31, 2023
Capnopharm receives CE certification for its new CapnoPen technology
Capnopharm’s new CapnoPen is the first PIPAC nebulizer to obtain CE marking under the new MDR regulation 2017/745
Capnopharm’s new CapnoPen is the first PIPAC nebulizer to obtain CE marking under the new MDR regulation 2017/745
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
It provides doctors with three indicators: identification of the bone, confirmation of device insertion into the bone, and notification in case of perforation through the opposite end of the bone
First approved therapeutic regimen that combines an anti-PD-1 and an antibody-drug conjugate in the US in these patients
China is among the top countries reporting a high number of diagnosed prevalent cases for gastric, breast, and bladder cancers among the 16 major markets
Clinical data to date shows efti uniquely positioned to address entire NSCLC patient population through both chemo-free IO-IO and IO-IO-chemo triple combinations
MoES have identified a potent Anti-cancer molecule named GS/IICT5/6
Twelve hospitals across India will be part of the network which will support the trial in India
The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
_256_384.png)
Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI
Subscribe To Our Newsletter & Stay Updated
